KR20090005410A - 항-Ａβ 항체 - Google Patents

항-Ａβ 항체 Download PDF

Info

Publication number
KR20090005410A
KR20090005410A KR1020087031635A KR20087031635A KR20090005410A KR 20090005410 A KR20090005410 A KR 20090005410A KR 1020087031635 A KR1020087031635 A KR 1020087031635A KR 20087031635 A KR20087031635 A KR 20087031635A KR 20090005410 A KR20090005410 A KR 20090005410A
Authority
KR
South Korea
Prior art keywords
antibody
peptide
antibodies
gel
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087031635A
Other languages
English (en)
Korean (ko)
Inventor
로날드 브래들리 디매터스
우마 쿠치보틀라
시우-치웅 양
돈 비. 맥클루어
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20090005410A publication Critical patent/KR20090005410A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
KR1020087031635A 2004-02-23 2005-02-17 항-Ａβ 항체 Ceased KR20090005410A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
US60/546,764 2004-02-23

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020067016812A Division KR100889430B1 (ko) 2004-02-23 2005-02-17 항-Ａβ 항체

Publications (1)

Publication Number Publication Date
KR20090005410A true KR20090005410A (ko) 2009-01-13

Family

ID=34910810

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020087031635A Ceased KR20090005410A (ko) 2004-02-23 2005-02-17 항-Ａβ 항체
KR1020067016812A Expired - Fee Related KR100889430B1 (ko) 2004-02-23 2005-02-17 항-Ａβ 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067016812A Expired - Fee Related KR100889430B1 (ko) 2004-02-23 2005-02-17 항-Ａβ 항체

Country Status (20)

Country Link
US (1) US20070190046A1 (https=)
EP (1) EP1720909B1 (https=)
JP (1) JP4851348B2 (https=)
KR (2) KR20090005410A (https=)
CN (1) CN1922209B (https=)
AT (1) ATE534667T1 (https=)
AU (1) AU2005217596B2 (https=)
BR (1) BRPI0507856A (https=)
CA (1) CA2556436C (https=)
CY (1) CY1112162T1 (https=)
DK (1) DK1720909T3 (https=)
EA (1) EA009872B1 (https=)
ES (1) ES2375627T3 (https=)
IL (1) IL177611A (https=)
NO (1) NO20064239L (https=)
PL (1) PL1720909T3 (https=)
PT (1) PT1720909E (https=)
SI (1) SI1720909T1 (https=)
UA (1) UA93181C2 (https=)
WO (1) WO2005082939A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
KR20120017469A (ko) 2007-01-05 2012-02-28 유니버시티 오브 취리히 질환 특이적 결합 분자 및 표적을 제공하는 방법
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
JP2010515717A (ja) 2007-01-11 2010-05-13 フィリップス−ウニベルジテート・マールブルク アルツハイマーおよび他の神経性認知症疾患の診断ならびに処置
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
SG178809A1 (en) * 2007-10-05 2012-03-29 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
JP5773879B2 (ja) 2008-11-25 2015-09-02 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 神経系の細胞の生存を促進するためのＤＲ６およびｐ７５のアンタゴニストの使用
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
KR20120103587A (ko) 2009-11-12 2012-09-19 제넨테크, 인크. 수상돌기 소극 밀도를 증진시키는 방법
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
PT3042917T (pt) * 2010-08-12 2018-05-02 Lilly Co Eli Anticorpos do péptido beta amilóide anti-n3pglu e seus usos
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
HUE041391T2 (hu) 2011-06-23 2019-05-28 Biogen Int Neuroscience Gmbh Anti-alfa-szinukleinkötõ molekulák
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
CA2883896C (en) 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6840774B2 (ja) 2016-05-16 2021-03-10 ザ ジェネラル ホスピタル コーポレイション 肺上皮エンジニアリングにおけるヒト気道幹細胞
JP2019524788A (ja) * 2016-08-11 2019-09-05 イーライ リリー アンド カンパニー アミノチアジンおよびｂａｃｅ１阻害剤としてのそれらの使用
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2023150483A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
BRPI0108676B8 (pt) * 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide

Also Published As

Publication number Publication date
CN1922209B (zh) 2012-09-05
DK1720909T3 (da) 2012-01-30
PL1720909T3 (pl) 2012-04-30
WO2005082939A2 (en) 2005-09-09
IL177611A (en) 2013-05-30
AU2005217596A1 (en) 2005-09-09
AU2005217596B2 (en) 2012-01-19
KR100889430B1 (ko) 2009-03-23
ES2375627T3 (es) 2012-03-02
SI1720909T1 (sl) 2012-01-31
CY1112162T1 (el) 2015-12-09
CN1922209A (zh) 2007-02-28
KR20060126785A (ko) 2006-12-08
BRPI0507856A (pt) 2007-07-10
CA2556436C (en) 2014-04-01
EP1720909A2 (en) 2006-11-15
EA009872B1 (ru) 2008-04-28
PT1720909E (pt) 2011-12-23
EA200601545A1 (ru) 2007-02-27
CA2556436A1 (en) 2005-09-09
JP2008500279A (ja) 2008-01-10
WO2005082939A3 (en) 2005-10-27
NO20064239L (no) 2006-11-20
UA93181C2 (ru) 2011-01-25
EP1720909B1 (en) 2011-11-23
US20070190046A1 (en) 2007-08-16
IL177611A0 (en) 2006-12-10
JP4851348B2 (ja) 2012-01-11
ATE534667T1 (de) 2011-12-15

Similar Documents

Publication Publication Date Title
KR100889430B1 (ko) 항-Ａβ 항체
US11078261B2 (en) Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
KR102076384B1 (ko) 타우병증을 치료하는 방법
US11919947B2 (en) Antibody binding active α-synuclein
ES2567437T3 (es) Oligómeros beta-(1,42) amiloides, derivados de los mismos y anticuerpos para estos, métodos para la preparación de los mismos y uso de los mismos
RU2731713C2 (ru) Применение il-18-связывающего белка (il-18bp) при воспалительных заболеваниях
ES2934656T3 (es) Anticuerpos antitranstiretina
US20180127494A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
BR112019017001A2 (pt) composição, proteína de fusão, ácido nucleico, célula hospedeira, e, métodos para produção de um domínio de aglutinação de albumina, para preparação de uma variante de il-15, para produção de uma proteína de fusão e para inibição ou redução de um tumor em um indivíduo em necessidade do mesmo.
EA012162B1 (ru) Способ рефолдинга рекомбинантных антител
JP2003523764A (ja) Ａβペプチドを隔離するヒト化抗体
PT821695E (pt) Purificação de anticorpos por cromatografia de interacção hidrofóbica a ph baixo
KR20160037173A (ko) 치료학적 융합 단백질
RS60883B1 (sr) Metodi lečenja tauopatije
WO1999059636A1 (en) Vegf activity inhibitors
TWI734279B (zh) 抗α-突觸核蛋白抗體及其用途
TW202019481A (zh) 末稍神經障礙或伴隨著觀察到末稍神經障礙或星狀細胞障礙之疾病的疼痛之預防或治療方法
CN114213541B (zh) 一种全能核酸酶的单克隆抗体及其制备方法
MXPA06009560A (en) Anti-abeta antibody
WO2023238869A1 (ja) 筋萎縮性側索硬化症、パーキンソン病、ハンチントン病、脊髄小脳失調症、老化に関連する変性疾患若しくは神経疾患、脳老化、あるいは脳老化を伴う疾患の予防剤又は治療剤
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20081226

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090202

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20090530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20090202

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20090701

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20090530

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20110113

Appeal identifier: 2009101006195

Request date: 20090701

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090701

Effective date: 20110113

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20110113

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20090701

Decision date: 20110113

Appeal identifier: 2009101006195